Author

D. Papadopoulou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Tzaferis· 2 shared F. Roumelioti· 2 shared G. Kollias· 2 shared M. Denis· 2 shared N. Karagianni· 2 shared P. Chouvardas· 2 shared A. Andrikos· 1 shared A. Liakos· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. Tzaferis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Repurposing of Amisulpride, a known antipsychotic drug, to target synovial fibroblasts activation in arthritis.

D. Papadopoulou, F. Roumelioti, C. Tzaferis, P. Chouvardas, A.-K. Pedersen, F. Charalampous, E. Christodoulou-Vafeiadou, L. Ntari, N. Karagianni, M. Denis, J. V. Olsen, A. N. Matralis, G. Kollias

This study identifies Amisulpride as a potential therapeutic for arthritis by reducing synovial fibroblast activation, independent of its known targets.

bioRxiv · Aug 2, 2022 · PreprintPharmacology & Toxicology

miR-221/222 drive synovial fibroblast expansion and pathogenesis of TNF-mediated arthritis

F. Roumelioti, C. Tzaferis, D. Konstantopoulos, D. Papadopoulou, A. Prados, M. Sakkou, A. Liakos, P. Chouvardas, T. Meletakos, Y. Pandis, N. Karagianni, M. Denis, M. Fousteri, M. Armaka, G. Kollias

This study shows miR-221/222 promotes synovial fibroblast expansion and worsens TNF-mediated arthritis by regulating cell cycle and ECM pathways.

bioRxiv · Jul 22, 2022 · PreprintCell Biology

Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy

M. Stangou, S. Marinaki, E. Papachristou, K. Kolovou, E. Sambani, S. Zerbala, P. Papadea, O. Balafa, K.-P. Rapsomanikis, A. Andrikos, P. Manolakaki, D. Papadopoulou, E. Mitsopoulos, P.-E. Andronikidi, V. Choulitoudi, , A. Papagianni

This study compares long-term outcomes of Cyclophosphamide and Calcineurin inhibitors in Primary Membranous Nephropathy, finding Cyclophosphamide associated with better renal function preservation and lower relapse rates.

bioRxiv · May 8, 2019Immunology